Impact on Patient Outcomes: Evaluation of Waitemata DHB's Medicine Use Review Service.

Show simple item record Bye, Lynne en Ali, A en Clark, T en Davis, K en Hong, Y en Crump, K en Harrison, J en
dc.contributor.editor Emmerton, L en
dc.contributor.editor Peters, A en
dc.contributor.editor Ross, D en
dc.contributor.editor Ross, B en
dc.coverage.spatial Brisbane, Australia en 2012-05-23T23:36:43Z en 2010-12-08 en
dc.identifier.citation Australasian Pharmaceutical Science Association Annual Conference, Brisbane, Australia, 06 Dec 2010 - 09 Dec 2010. en
dc.identifier.citation en
dc.identifier.isbn 9780646548050 en
dc.identifier.uri en
dc.description.abstract Medicine Use Review (MUR) is a medication counselling and adherence support service involving an initial consultation with an accredited pharmacist and two follow-ups over one year which is funded by the Waitemata District Health Board (WDHB) in NZ. OBJECTIVE: To evaluate the effect of the WDHB MUR service on the outcomes of care for enrolled patients. METHOD: The study population was 493 patients enrolled into the WDHB MUR service from October 2007 to August 2010. Service documentation, EuroQol questionnaire (1), pharmacist interview and hospital admission data were evaluated. Medicine related problems (MRPs) identified, interventions recommended and reported outcomes were collated and coded using a modification of the PCNE (Drug Related Problem classification) (2). The interview data was analysed using a general inductive theme analysis. RESULTS: From a sample of 477 patients, 1595 MRPS were identified with the majority being fully resolved. Quality of life (QOL) scores increased from the initial consultation to follow-up two. Hospital admissions and length of stay decreased between the year before MUR and two years following. Themes from the interview included; increased adherence, improved ability to self-manage medicines and decreased General Practice visits. DISCUSSION: The WDHB MUR service has been shown to resolve MRPs, improve QOL and reduce hospitalisations. 1. Brooks R. EuroQol: The current state of play. Health policy. 1996;37. 2. Pharmaceutical Care Network Europe Foundation. The PCNE Classification V 5.01. 2006. en
dc.publisher Australasian Pharmaceutical Science Association en
dc.relation.ispartof Australasian Pharmaceutical Science Association Annual Conference en
dc.relation.ispartofseries Proceedings of the Australasian Pharmaceutical Science Association Annual Conference 2010 en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.title Impact on Patient Outcomes: Evaluation of Waitemata DHB's Medicine Use Review Service. en
dc.type Presentation en
pubs.begin-page 84 en
dc.rights.holder Copyright: Australasian Pharmaceutical Science Association; The Authors en
pubs.finish-date 2010-12-09 en
pubs.start-date 2010-12-06 en
dc.rights.accessrights en
pubs.subtype Conference Oral Presentation en
pubs.elements-id 205420 en Medical and Health Sciences en Pharmacy en
pubs.record-created-at-source-date 2011-02-08 en

Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace